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Abstract The objective of this study is to assess swal-
lowing and speech outcome after chemoradiation therapy
for head and neck cancer, based on the patient-reported
outcome measures Swallowing Quality of Life Question-
naire (SWAL-QOL) and Speech Handicap Index (SHI),
both provided with cut-off scores. This is a cross-sectional
study. Department of Otolaryngology/Head and Neck
Surgery of a University Medical Center. Sixty patients,
6 months to 5 years after chemoradiation for head and
neck squamous cell carcinoma. Swallowing Quality of Life
Questionnaire (SWAL-QOL) and SHI, both validated in
Dutch and provided with cut-off scores. Associations were
tested between the outcome measures and independent
variables (age, gender, tumor stage and site, and radio-
therapy technique, time since treatment, comorbidity and
food intake). Fifty-two patients returned the SWAL-QOL
and 47 the SHI (response rate 87 and 78 %, respectively).
Swallowing and speech problems were present in 79 and
55 %, respectively. Normal food intake was noticed in 45,
35 % had a soft diet and 20 % tube feeding. Patients with
soft diet and tube feeding reported more swallowing
problems compared to patients with normal oral intake.
Tumor subsite was significantly associated with swallow-
ing outcome (less problems in larynx/hypopharynx com-
pared to oral/oropharynx). Radiation technique was
significantly associated with psychosocial speech problems
(less problems in patients treated with IMRT). Swallowing
and (to a lesser extent) speech problems in daily life are
frequently present after chemoradiation therapy for head
and neck cancer. Future prospective studies will give more
insight into the course of speech and swallowing problems
after chemoradiation and into efficacy of new radiation
techniques and swallowing and speech rehabilitation
programs.
Keywords Swallowing  Speech  Patient-reported
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Introduction
Advanced head and neck cancer is increasingly being
treated with organ-preservation protocols such as
chemoradiation therapy (CHRT). Organ-preservation pro-
tocols aim, next to the foremost goal to cure the disease,
also at maintenance of respiration, deglutition, speech,
phonation and cosmetics. However, literature reviews
revealed that organ-preservation protocols often result in
swallowing impairment; also speech problems may occur
but these are investigated less often [1–5]. Most of the
studies included in these reviews focused on swallowing
impairment using videofluoroscopy, fiberoptic endoscopic
evaluation of swallowing (FEESTM),or toxicity grading
protocols, but recent studies involve patient-reported
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outcomes measures as well [6–10]. Information from
objective imaging techniques regarding swallowing
impairment is important but does not necessarily relate to
patient-reported swallowing outcomes [11–14]. There is
broad range of variety of questionnaires used to evaluate
swallowing and speech outcomes and the impact on quality
of life [2, 15]. The head and neck cancer modules
accompanying the EORTC and FACT Quality of Life
Questionnaires or the University of Washington Quality of
Life Questionnaire are often used. Studies using specific
swallowing and speech-specific questionnaires like the MD
Anderson Dysphagia Index (MDADI) [16] or the Swal-
lowing Questionnaire on Quality of Life (SWAL-QOL)
[17, 18], or the Speech Handicap index (SHI) [19] to assess
speech or swallowing problems in daily life after
chemoradiation therapy are less often reported.
The goal of the present cross-sectional study was to
assess the prevalence of patient-reported speech and
swallowing outcome after chemoradiation therapy for
head and neck cancer. Measures were chosen that are
provided with clear cut-off values: the Dutch versions of
the Swallowing Quality of Life Questionnaire (SWAL-
QOL) and the Speech Handicap Index (SHI), which
enables quantification of patient-reported speech and
swallowing problems in daily life [18, 19]. Furthermore,
insight will be obtained regarding the association of
sociodemographic (age and gender) and clinical factors
{comorbidity [Adult Comorbidity Evaluation 27 (ACE-
27)] [20], tumor site and stage, radiotherapy scheduling,
time since treatment} and food intake (normal, soft diet,




The study was conducted according to regular procedures
of the local ethical committee of the VU University Med-
ical Center, Amsterdam. All patients provided informed
consent.
Patients
Inclusion criteria comprised primary head and neck carci-
noma (all subsites, all stages) and chemoradiation treat-
ment. One hundred and three patients with primary head
and neck carcinoma underwent CHRT of which 71 were
alive at the time of the study. Seven patients were excluded
because of distant metastasis or loco-regional recurrence
and 4 patients were excluded because they did not speak
Dutch, leaving a study cohort of 60 patients.
Data on age, gender, comorbidity, and tumor and
treatment characteristics [site and stage (according to
UICC)], radiation technique, time since treatment, place-
ment and removal of gastrostomy tube were collected from
the medical records. Comorbidity was assessed with the
Adult Comorbidity Evaluation 27 (ACE-27) [20]. The
ACE-27 includes 27 comorbid conditions, including car-
diovascular, respiratory, gastro-intestinal, renal, endocrine,
neurological, immunological, psychiatric and rheumato-
logic disorders, previous or synchronous malignancy,
alcohol abuse and excessive body weight. The ACE-27 was
designed specifically for cancer patients and classifies
patients into 4 grades of comorbidity [none (grade 0), mild
(grade 1), moderate (grade 2), severe (grade 3)].
During a time span of 8 months, 52 out of 60 patients
returned the SWAL-QOL (response rate 87 %) and 47, the
SHI (response rate 78 %). An overview of patient charac-
teristics is provided in Table 1. Median age of the patients
was 58 years (range 36–75). Thirty-five (67 %) of the
patients were male. No comorbidity was observed in 16
patients, 24 patients had grade 1, 8 patients grade 2 and 4
patients grade 3. Primary tumor locations were oral cavity
(n = 5), oropharynx (n = 30), nasopharynx (n = 4), lar-
ynx (n = 10) and hypopharynx (n = 3) and these were
categorized into oral cavity/oropharynx/nasopharynx
(n = 39) and larynx/hypopharynx (n = 13) for comparison
and statistical analyses. Overall tumor stages were II
(n = 2), III (n = 18) and IV (n = 32), which were cate-
gorized into stage II–III (n = 20) vs. IV (n = 32) for
comparison and statistical analyses. Almost all (97 %)
Table 1 Overview of patient
characteristics (n = 52)
Gender
Male 35 (67 %)
Female 17 (33 %)
Comorbidity
None 16 (31 %)
Grade 1 24 (46 %)
Grade 2 8 (15 %)
Grade 3 4 (8 %)
Tumor site
Oral cavity 5 (9 %)
Oropharynx 30 (58 %)
Nasopharynx 4 (8 %)
Larynx 10 (19 %)
Hypopharynx 3 (6 %)
Tumor stage
II/III 23 (44 %)
IV 29 (56 %)
Radiotherapy
3D-CRT 31 (60 %)
IMRT 21 (40 %)
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patients underwent PEG placement at start of treatment.
All patients underwent chemoradiation, in 79 % of the
patients consisting of Cisplatin 100 mg/m2 in 3 cycles. Of
the remaining patients, 4 % received 1 cycle and 12 %
received 2 cycles. Three patients (6 %) underwent intra-
arterial Cisplatin 150 mg/m2 in 4 cycles. Chemotherapy
was given concomitantly with radiotherapy (2 Gy per
fraction, 5 times per week, total dose of 70 Gy). One
patient received also 5-Fluor-Uracil because of cisplatin
side-effects after 1 cycle. In 31 patients, conventional
three-dimensional conformal radiotherapy (3D-CRT) was
given and intensity-modulated radiation therapy (IMRT) in
21 patients. Patients treated before 2005 were treated with
3D-CRT, without sparing the salivary glands. In 2005,
IMRT was introduced as part of standard care at the
department of radiation oncology enabling a significant
reduction of the dose to the salivary glands. The gastros-
tomy tube was removed in 80 % after complete remission
and when oral intake was sufficient (in average 3–6 months
after end of treatment). Time since treatment ranged from 6
to 58 months with a median of 21 months.
Patient-reported outcomes
Swallowing and speech impairment was measured via the
Swallowing Questionnaire on Quality of Life (SWAL-
QOL) and the Speech Handicap Index (SHI).
The SWAL-QOL is a 44-item questionnaire on swal-
lowing-related problems in daily life [17, 18]. Response
categories range on a 5-point scale. There are 10 subscales:
(1) food selection (2 items); (2) eating duration (2 items);
(3) eating desire (3 items); (4) Fear (4 items); (5) burden (2
items); (6) mental health (5 items); (7) social functioning (5
items); (8) communication (2 items); (9) sleep (2 items);
and (10) fatigue (3 items). Furthermore, there is an overall
symptom scale (14 items). Finally, a total SWAL-QOL
Score can be calculated (based on the 23 items of the first 7
scales listed above). All SWAL-QOL scales range from 0
to 100, a higher score indicating more impairment. Three
single questions are included regarding nutrition intake
(‘‘normal’’, ‘‘soft’’, ‘‘pureed’’, ‘‘liquids only’’, ‘‘mostly tube
feeding’’ and ‘‘tube feeding only’’), liquid intake (‘‘all
liquids’’, ‘‘thick liquids’’, ‘‘very thick liquids’’, ‘‘thickened
liquids’’ and ‘‘no liquids’’), and general health (‘‘poor’’,
‘‘moderate’’, ‘‘good’’, ‘‘very good’’ and ‘‘excellent’’). The
SWAL-QOL was translated and validated for use in Dutch
head and neck cancer patients. A cut-off score on the total
SWAL-QOL score of 14 points (or higher) (94 % sensi-
tivity and 84 % specificity) indicates swallowing problems
in daily life [18].
The SHI is a validated speech-specific quality of life
questionnaire and consists of 30-items focusing on speech-
related problems in daily life. Response categories range on
a 5-point Likert scale (‘‘never’’, ‘‘almost never’’, ‘‘some-
times’’, ‘‘almost always’’ and ‘‘always’’). The questionnaire
also includes an overall speech quality item, with 4
response categories (‘‘good’’, ‘‘reasonable’’, ‘‘poor’’ and
‘‘severe’’). A total SHI score is calculated by summing the
scores on all 30 items (score range 0–120), with a higher
score indicating a higher level of speech-related problems.
Two subscales are distinguished: psychosocial function and
speech function. A total SHI score C6 indicates speech
problems in daily life (95 % sensitivity and 90 % speci-
ficity) [19].
Statistical analyses
Descriptive statistics were calculated for the SWAL-QOL
and SHI scales. A t test for independent groups was used to
test differences between patients regarding gender (male
vs. female), tumor site (larynx/hypopharynx vs. oral cavity/
oropharynx/nasopharynx), tumor stage (stage I–II vs. stage
III–IV) and type of radiotherapy (3D vs. IMRT) on SWAL-
QOL and SHI scores. Analysis of variance (ANOVA) was
carried out to test differences regarding comorbidity (grade
0, 1, 2 or 3) and food intake (normal, soft diet, pureed diet,
tube feeding). In case of overall significant differences,
post hoc analyses were carried out to pairwise compare all
different groups. Bonferroni correction was applied to
correct for multiple testing. Correlation analyses were
performed to study the relation between age (Pearson) and
time since treatment (Spearman’s rank) and SWAL-QOL
and SHI scores, and to study the relation between the total
SWAL-QOL scale and the total SHI scale. Those variables
that showed univariate significant relations with the out-
come measures, were included into the multivariate
regression analysis (stepwise) to obtain insight into which
sociodemographic (age, gender) and clinical (comorbidity,
tumor site and stage, radiation technique, time since
treatment) parameters are associated with patient-reported
speech and swallowing outcome. For all statistical tests,
significance was defined as p\ 0.05. All analyses were
performed using the IBM Statistical Package for the Social




A deviant SWAL-QOL score (total SWAL-QOL
score C14) was observed in 79 % of the patients (41/52).
Mean scores are presented in Table 2. Relatively high
scores were observed on the subscales general burden, food
selection, eating duration, eating desire, fatigue and sleep.
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Normal food intake was reported by 23 patients (45 %),
while 18 (35 %) took a soft diet or pureed food, and 10
(20 %) had tube feeding (data were missing for 1 patient).
Patients with normal food intake had significantly better
mean scores compared to patients with soft diet or tube
feeding on all SWAL-QoL scales, except for the subscales
sleep and fatigue; patients with soft diet or tube feeding did
not differ from each other significantly on any of the scales
(Table 2).
Univariate analyses revealed that age, gender, comor-
bidity and tumor stage were not significantly related to
SWAL-QOL scores. Swallowing outcome was signifi-
cantly associated with tumor site and radiotherapy tech-
nique. Patients treated for a laryngeal or hypopharyngeal
tumor had significantly (p\ 0.05) better scores compared
to patients treated for an oral cavity, oropharyngeal or
nasopharynx tumor on the total SWAL-QOL (df = 50;
t = -2.10; p = 0.041) and the subscales general burden
(df = 50; t = -2.23; p = 0.030), mental health (df = 50;
t = -2.30; p = 0.026) and social functioning (df = 50;
t = -2.46; p = 0.017). Compared to 3D-CRT, patients
after IMRT had significantly better scores on the total
SWAL-QOL (df = 49.9; t = 2.22; p = 0.031), food
selection (df = 50; t = 2.01; p = 0.05), fear of eating
(df = 50; t = 3.34; p = 0.002), sleep (df = 50; t = 2.89;
p = 0.006) and social functioning (df = 50; t = 2.46;
p = 0.018). Furthermore, a positive correlation (more
problems on the long term) was found between time since
treatment and the following SWAL-QOL subscales:fear of
eating (q = 0.57; p\ 0.001), sleep (q = 0.41; p = 0.002),
fatigue (q = 0.33; p = 0.015), social function (q = 0.33;
p = 0.019) and the total SWAL-QOL score (q = 0.37;
p = 0.007).Because radiotherapy technique was related to
time since treatment, correlation coefficients were also
calculated in these subgroups (3D-CRT vs. IMRT) and no
significant relations between time since treatment and
swallowing outcome were found.
For the multivariable regression analysis only tumor site
and radiotherapy technique were included in the selection
procedure, which revealed that only tumor site was sig-
nificantly associated with the total SWAL-QOL score
(B = 15.5, R2 = 0.081, F = 4.40, p = 0.041). Note that
radiotherapy technique is univariate more significantly
associated to total SWAL-QOL, but this factor did not
enter the multivariate model due to unequal variances of
the two groups.
Table 2 Summary of mean scores (SD) of all patients on the subscales of the SWAL-QOL and the SHI, and regarding food intake (normal diet






















35.4 (19.5) 23.8 (19.0) 43.7 (15.3) 49.6 (10.7) \0.001 0.001 0.001 1.00
General burden 42.7 (30.4) 25.1 (29.2) 60.6 (22.8) 52.6 (24.2) \0.001 \0.001 0.023 1.00
Food selection 45.8 (34.0) 20.7 (24.6) 69.0 (20.1) 66.5 (30.0) \0.001 \0.001 \0.001 1.00
Eating duration 56.9 (32.2) 38.2 (30.1) 73.7 (21.0) 72.6 (31.5) \0.001 \0.001 0.005 1.00
Eating desire 39.8 (31.9) 19.5 (27.5) 51.3 (20.6) 69.9 (25.0) \0.001 0.001 \0.001 0.19
Fear of eating 30.2 (24.4) 21.8 (22.0) 42.6 (22.2) 30.1 (25.8) 0.021 0.017 1.00 0.52
Sleep 49.5 (31.3) 39.8 (29.7) 59.3 (25.6) 53.9 (41.3) 0.13 0.15 0.71 1.00
Fatigue 47.1 (24.3) 43.1 (29.2) 47.7 (17.2) 55.0 (24.3) 0.44 1.00 0.62 1.00
Communication 32.3 (29.2) 20.7 (23.8) 38.3 (30.4) 46.3 (32.4) 0.034 0.15 0.059 1.00
Mental health 30.6 (26.5) 16.1 (19.8) 44.4 (22.2) 41.0 (31.6) 0.001 0.001 0.021 1.00
Social FX 28.8 (25.8) 13.5 (17.1) 43.3 (26.0) 40.5 (22.5) \0.001 \0.001 0.006 1.00
SHI (total score) 18.6 (21.8) 11.7 (15.2) 22.8 (27.7) 29.3 (22.6) 0.11 0.38 0.19 1.00
SHI psychosocial
subscale
6.7 (10.7) 3.0 (6.4) 10.2 (13.7) 10.3 (11.2) 0.069 0.11 0.33 1.00
SHI speech
quality subscale
11.8 (12.0) 8.4 (10.1) 12.7 (13.5) 18.7 (11.8) 0.12 0.84 0.14 0.79
Statistical significant differences (p\ 0.05) are printed bold
* p values are corrected with the Bonferroni correction to account for multiple testing
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Patient-reported speech outcome
A deviant SHI score (total SHI score C6) was observed in
55 % of the patients (26/47). Mean scores are presented in
Table 2. Univariate analyses revealed that radiotherapy
technique was associated significantly with the subscale
SHI psychosocial function: patients treated with IMRT had
a better score (df = 39.7; t = 2.48; p = 0.017). Age,
gender, comorbidity, tumor stage and site, and time since
treatment (corrected for radiotherapy technique) were not
significantly associated with SHI total scores. Therefore, no
multivariate regression analyses were carried out.
Relation between swallowing and speech outcome
A significant relation between swallowing and speech
outcome was found: Pearson r was 0.56, p\ 0.001
regarding the total scores on the SWAL-QOL and SHI.
Regarding the presence of swallowing and speech prob-
lems (score above cut-off value), 51 % of the patients after
chemoradiation had both speech and swallowing problems,
24 % had swallowing problems but no speech problems,
7 % had speech problems but no swallowing problems and
18 % had no speech or swallowing problems.
Discussion
The present study revealed a high prevalence of patient-
reported swallowing (79 %) and speech (55 %) problems
after chemoradiation for advanced head and neck cancer.
Swallowing and speech problems were significantly related
to each other, indicating that many patients who experience
swallowing problems also experience speech problems.
The prevalence of swallowing and speech problems after
(chemo)radiotherapy in earlier studies differ considerably
depending among others on the assessment methods [2,
15]. Unlike earlier studies, the percentages in the present
study are based on validated cut-off values of the SWAL-
QOL and SHI questionnaires.
Swallowing problems can lead to clinically apparent as
well as silent aspiration or continued alternate feeding such
as feeding tube placement [33, 34]. Recently, Kano et al.
[35] compared the need for tube feeding support among
patients treated with surgery (26 %) vs. chemoradiation
(12 %), as assessed immediately after initial treatment. In
the present study, 20 % of the patients after CHRT had
tube feeding, almost all within 18 months after treatment,
which falls in the broad range as reported in the literature
varying from 20 to 60 % use of a feeding tube at 1 year
after treatment to 8–18 % longer term use [36, 37]. As
expected, patients with tube feeding as well as patients
with soft or pureed diet in the present study had more
swallowing problems compared to patients with normal
oral food intake. Dysphagia is known to have a major
impact on quality of life, in particular in patients with tube
feeding [38–40]. Severe dysphagia is also related to
increased emotional distress, not only of the patients
themselves but also of their spouses [41, 42].
In the present study, swallowing and speech problems
were significantly related to tumor subsite (patients treated
for oral or oropharynx cancer had significantly more
swallowing problems compared to patients treated for lar-
ynx or hypopharynx cancer) and radiation technique (pa-
tients treated with IMRT reported less swallowing and
speech problems). There are several causes that may
explain these differences. Detailed studies on swallowing
after (chemo)-radiation for head and neck cancer revealed a
large variety of motility disorders, including prolonged oral
transit time, decreased tongue strength/control, reduced
base of tongue contact to the pharyngeal wall, pharyngeal
constrictor dysmotility, decreased laryngeal elevation,
reduced hyoid movement and epiglottic dysmotility [21–
25]. The probability of swallowing dysfunction after
(chemo)radiation appears to be associated with radiation-
induced thickening of the pharyngeal constrictor muscles,
the supraglottic larynx and the glottic larynx [26, 27].
Furthermore a clear relationship is found between dose
distributions in the salivary glands and subjective xeros-
tomia [28, 29]. Chemotherapy functions as a sensitizer for
radiotherapy and enhances the effects of radiotherapy on
the tumor and the surrounding tissue. The cytotoxic effects
of chemotherapy alone on oral, pharyngeal and laryngeal
mucosa also lead to oral mucositis, infections, xerostomia,
and neutropenia are associated with long-term swallowing
problems, not only in head and neck cancer patients [30,
31], but also in, for example, breast, colon or lung cancer
patients [32].
The prevalence of swallowing dysfunction and the
major impact of this side effect on the more general
dimensions of health-related quality of life stresses the
importance of effective preventive measures and/or thera-
peutic interventions. New radiation delivery techniques
aiming at sparing of anatomical structures that are corre-
lated with swallowing may contribute to prevent long-term
radiation-induced dysphagia [43–45]. Another possibility is
speech and swallowing rehabilitation. In usual care, reha-
bilitation includes pretreatment evaluation of swallowing
and counseling allowing to determine the swallowing sta-
tus at start and to prepare the patient regarding possible
swallowing impairment and the rehabilitation process and
post treatment speech and swallowing management
strategies consisting of oromotor exercises (to increase the
strength and mobility of the lips, tongue and mandible),
swallow maneuvers (to facilitate swallowing function and
to prevent aspiration) and compensation techniques
Eur Arch Otorhinolaryngol (2016) 273:1849–1855 1853
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(adjusting posture, adjusting food consistency). It has been
argued that patients should be encouraged to swallow
throughout their treatment also when prophylactic feeding
tube is placed. Recent studies reveal that exercises in an
early stage, before and during radiotherapy, may prevent or
decrease swallowing dysfunction after curative (chemo)-
radiation [5, 46–49], but not all studies show these bene-
ficial effects [50]. There is growing evidence that attention
is needed for the individual needs of the patients to
determine the best rehabilitation strategy [51, 52].
Prospective randomized trials are needed to provide evi-
dence-based effectiveness of these approaches.
It can be concluded that swallowing and (to a lesser
extent) speech problems in daily life are frequently repor-
ted by patients after chemoradiation therapy for advanced
head and neck cancer. Future prospective studies will give
more insight into the course of speech and swallowing
problems after chemoradiation and into efficacy of new
radiation techniques and swallowing and speech
rehabilitation.
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